Zev A. Wainberg, MD, on Findings From the Updated KEYNOTE-062 Trial With Pembrolizumab/Chemo for Advanced Gastric/GEJ Adenocarcinoma

Video

In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, discussed key updates from the phase 3 KEYNOTE-062 trial (NCT02494583), examining pembrolizumab (Keytruda) alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma. Findings from the trial indicate that pembrolizumab does not currently have a role in the space when combined with chemotherapy. However, he noted that some of the non-inferiority findings have held up over the last 2 years.

Transcript:

The study has really held up over time. Unfortunately, there was still no role for the addition of pembrolizumab to chemotherapy over chemotherapy alone, which is of course, a distinction from the CheckMate-649 data, which did show a role for nivolumab in CPS greater than 5 patients over chemotherapy alone. [It's] a little bit of a contradiction, obviously, in the sense that there were 2 different drugs, both of which have activity in this disease, but one met its endpoint in this regard and one did not. Long-term follow up studies did show that, as a single agent, pembrolizumab noninferiority continued to reach its end point, if you regard that as an important endpoint.

What's interesting is that 2 years later, some of the efficacy or non-inferiority [findings] have held up with respect to pembrolizumab vs chemotherapy as a single agent, particularly in the patients with a CPS greater than 10, where the 2-year survival rate was nearly 40% with pembrolizumab vs 21% with chemotherapy alone. In the CPS greater than 10 patients, there is more bang for your buck with this agent without question. The hazard ratios and the medians slightly improved over the last few years, based on long-term follow up results. Of course, the field has changed so dramatically since then, [therefore] the relevance of it is questionable.

Reference

Wainberg ZA, Shitara K, Van Cutsem E, et al. Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. Presented at 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. January 20-22, 2022. Abstract 243.

Related Videos
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Related Content